Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa, Cyclophosphamide, and Busulfan for allo-HSCT in NK/T-Cell Lymphoma
NCT07276737Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of thiotepa in Natural killer T-cell lymphoma (NKTL), sponsored by Shanghai General Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
thiotepa
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT07276737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276737.